PMID- 37937729
OWN - NLM
STAT- MEDLINE
DCOM- 20231219
LR  - 20240123
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 12
IP  - 23
DP  - 2023 Dec
TI  - The clinical features and prognostic implications of PTPN11 mutation in adult 
      patients with acute myeloid leukemia in China.
PG  - 21111-21117
LID - 10.1002/cam4.6669 [doi]
AB  - BACKGROUND: The clinical significance of protein tyrosine phosphatase nonreceptor 
      type 11 mutation (PTPN11(mut) ) in acute myeloid leukemia (AML) is 
      underestimated. METHODS: We collected the data of AML patients with mutated 
      PTPN11 and wild-type PTPN11 (PTPN11(wt) ) treated at our hospital and analyzed 
      their clinical characteristics and prognosis. RESULTS: Fifty-nine PTPN11(mut) and 
      124 PTPN11(wt) AML patients were included. PTPN11(mut) was more common in 
      myelomonocytic and monocytic leukemia, and was more likely to co-mutate with 
      KRAS, KMT2C, NRAS, U2AF1, NOTCH1, IKZF1, and USH2A mutations than PTPN11(wt) . 
      The overall survival for AML patients with PTPN11(mut) was significantly shorter 
      than that for those with PTPN11(wt) (p = 0.03). The negative impact of 
      PTPN11(mut) on overall survival was pronounced in the "favorable" and 
      "intermediate" groups of ELN2017 risk stratification, as well as in the wild-type 
      NPM1 group (p = 0.01, p = 0.01, and p = 0.04). CONCLUSION: PTPN11(mut) is 
      associated with distinct clinical and molecular characteristics, and adverse 
      prognosis in AML patients.
CI  - (c) 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Yang, Jinjun
AU  - Yang J
AUID- ORCID: 0000-0001-8998-8796
AD  - Department of Hematology and Institute of Hematology, West China Hospital, 
      Sichuan University, Chengdu, China.
FAU - Zhao, Lei
AU  - Zhao L
AD  - Department of Hematology and Institute of Hematology, West China Hospital, 
      Sichuan University, Chengdu, China.
FAU - Wu, Yu
AU  - Wu Y
AUID- ORCID: 0000-0001-8708-9711
AD  - Department of Hematology and Institute of Hematology, West China Hospital, 
      Sichuan University, Chengdu, China.
FAU - Niu, Ting
AU  - Niu T
AD  - Department of Hematology and Institute of Hematology, West China Hospital, 
      Sichuan University, Chengdu, China.
FAU - Gong, Yuping
AU  - Gong Y
AD  - Department of Hematology and Institute of Hematology, West China Hospital, 
      Sichuan University, Chengdu, China.
FAU - Chen, Xinchuan
AU  - Chen X
AD  - Department of Hematology and Institute of Hematology, West China Hospital, 
      Sichuan University, Chengdu, China.
FAU - Huang, Xiaoou
AU  - Huang X
AD  - Department of Hematology and Institute of Hematology, West China Hospital, 
      Sichuan University, Chengdu, China.
FAU - Liu, Jiazhuo
AU  - Liu J
AD  - Department of Hematology and Institute of Hematology, West China Hospital, 
      Sichuan University, Chengdu, China.
FAU - Dai, Yang
AU  - Dai Y
AD  - Department of Hematology and Institute of Hematology, West China Hospital, 
      Sichuan University, Chengdu, China.
FAU - Ma, Hongbing
AU  - Ma H
AUID- ORCID: 0000-0002-1174-4078
AD  - Department of Hematology and Institute of Hematology, West China Hospital, 
      Sichuan University, Chengdu, China.
LA  - eng
GR  - 2022HXFH040/1.3.5 project for disciplines of excellence-Clinical Research 
      Incubation Project, West China Hospital, Sichuan University/
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20231108
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - 117896-08-9 (Nucleophosmin)
RN  - EC 3.1.3.48 (PTPN11 protein, human)
RN  - EC 3.1.3.48 (Protein Tyrosine Phosphatase, Non-Receptor Type 11)
SB  - IM
MH  - Adult
MH  - Humans
MH  - Prognosis
MH  - *Nucleophosmin
MH  - *Leukemia, Myeloid, Acute/drug therapy
MH  - Mutation
MH  - China/epidemiology
MH  - Protein Tyrosine Phosphatase, Non-Receptor Type 11/genetics
PMC - PMC10726903
OTO - NOTNLM
OT  - PTPN11
OT  - acute myeloid leukemia
OT  - event-free survival
OT  - overall survival
COIS- The authors declare no conflicts of interest.
EDAT- 2023/11/08 12:43
MHDA- 2023/12/19 06:41
PMCR- 2023/11/08
CRDT- 2023/11/08 07:13
PHST- 2023/10/03 00:00 [revised]
PHST- 2023/07/19 00:00 [received]
PHST- 2023/10/19 00:00 [accepted]
PHST- 2023/12/19 06:41 [medline]
PHST- 2023/11/08 12:43 [pubmed]
PHST- 2023/11/08 07:13 [entrez]
PHST- 2023/11/08 00:00 [pmc-release]
AID - CAM46669 [pii]
AID - 10.1002/cam4.6669 [doi]
PST - ppublish
SO  - Cancer Med. 2023 Dec;12(23):21111-21117. doi: 10.1002/cam4.6669. Epub 2023 Nov 8.